Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas

Authors
Category Primary study
JournalBlood
Year 2020
This article has no abstract
Epistemonikos ID: 170069d99853a9114c9c731def1a710f667d1331
First added on: Feb 12, 2025